Rockwell Medical (FRA:RWM) EPS without NRI: €-1.37 (TTM As of Mar. 2026)


FRA:RWM Rockwell Medical Inc FRA:RWM
30 GF Score
Price €5.25
GF Value €0.90
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical EPS without NRI?

Rockwell Medical FRA:RWM 30 EPS without NRI is €-1.37 as of Mar. 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 785 Drug Manufacturers companies, Rockwell Medical ranks better than 87.64% on this metric.

Rockwell Medical's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.37. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.37.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 50.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 60.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Rockwell Medical's EPS without NRI or its related term are showing as below:

FRA:RWM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -109.9   Med: 17.6   Max: 79.6
Current: 50.7

During the past 13 years, Rockwell Medical's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 79.60% per year. The lowest was -109.90% per year. And the median was 17.60% per year.

FRA:RWM's 3-Year EPS without NRI Growth Rate is ranked better than
87.64% of 785 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs FRA:RWM: 50.70

Rockwell Medical's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.29.

Rockwell Medical's EPS (Basic) for the three months ended in Mar. 2026 was €-0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.29.


Rockwell Medical  (FRA:RWM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Rockwell Medical EPS without NRI Related Terms


Rockwell Medical EPS without NRI Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical EPS without NRI Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.90 -12.37 -3.52 -0.31 -1.34

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.45 -0.44 -0.10 -0.37

FRA:RWM vs CPHI, TXMD, MRMD: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rockwell Medical PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's PE Ratio without NRI falls into.


FRA:RWM
30GF Score
Rockwell Medical Inc FRA:RWM
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rockwell Medical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-1.37 mean?
Rockwell Medical (FRA:RWM) has a EPS without NRI of €-1.37 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #97 out of 785 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Rockwell Medical's EPS without NRI too high?
Rockwell Medical's current EPS without NRI is €-1.37. Based on the distribution chart, Rockwell Medical ranks #97 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's EPS without NRI compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #97 out of 785 companies for EPS without NRI. This places Rockwell Medical in the top 12% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current EPS without NRI is €-1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current EPS without NRI is €-1.37. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current EPS without NRI is €-1.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for FRA:RWM:

  • EPS without NRI: €-1.37
  • GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWM

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€0.90
GF Value